The UK's drug safety regulator is asking doctors to be alert for patients who may be misusing obesity injections, such as ...

As obesity rates in the United States soar, insurance companies, including Medicaid and Medicare, are facing financial headwinds to pay for prescription drugs for weight loss. Semaglutide, the generic ...

Eli Lilly (LLY) is reportedly preparing to launch Mounjaro in Denmark, the home country of its leading rival in the ...

Weight-loss jabs are not a quick fix for an “Instagram body”, the Health Secretary has warned. The medicines regulator has ...

People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared ...

Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo ...

While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has ...

The active ingredient found in popular medications for Type 2 diabetes and weight loss, including Ozempic and Wegovy, may ...

Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition ...

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a ...